Ocular Therapeutix (OCUL) Stock Price, Quote, News & History | Benzinga

SPY780.27+0.22%QQQ752.45+0.16%BTC/USD83,618.87−0.07%DIA516.97+0.17%GLD382.83−0.46%TLT77.97−0.01%

Ocular Therapeutix Inc (OCUL) Stock Price, Quote, News & History

OCULNASDAQ

Trade with Public

Trade with Public

$7.54

0.030.4%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$7.54

Volume / Avg.

- / 2.79M

Day Range

- - -

52 Wk Range

6.23 - 16.44

Market Cap

$1.66B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

35

Short Interest

15.81%

Days to Cover

7.25

Recent Ocular Therapeutix, Inc. News

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter

Oversold health care stocks Align Technology, Dianthus Therapeutics and Ocular Therapeutix show RSI readings near or below 30, signaling potential value.

Avi Kapoor

Why Is Ocular Therapeutix Stock Gaining Monday?

Ocular Therapeutix stock jumps 6% as rival EyePoint misses Phase 3 primary endpoint for wet AMD treatment Duravyu.

Vandana Singh

H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Monday

H World Group (HTHT) beats earnings and raises sales guidance, shares jump 8.1%. Other big gainers include ANGX, ARGX, and MESO.

Avi Kapoor

Ocular Therapeutix Maps Regulatory Strategy For Lead Drug Program

Ocular outlines FDA-aligned AXPAXLI NDA plan for wet AMD by Q4 2026, revises SOL-R study design, and streamlines DR program.

Vandana Singh

Dole Posts Downbeat Q1 Earnings, Joins Ocular Therapeutix And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures down 0.1%, Dole PLC drops 5.9% after missing earning estimates, other stocks also decline in pre-market trading.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-238.24M

Investing Cash Flow (TTM)

-16.86M

Financing Cash Flow (TTM)

462.61M

Free Cash Flow (TTM)

-255.10M

Capital Expenditure (TTM)

-16.86M

Net Change in Cash (TTM)

207.51M

Analyst Trends and Forecast

3

Jun

1

Aug

3

Sep

1

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.14B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

31.00

PB Ratio (TTM)

3.18

Earnings Yield % (TTM)

-18.57%

Earnings Yield % (FWD)

-19.69%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$2.37

Company Debt

Total Debt

$72.80M

LT Debt

$72.80M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$598.64M

Debt to Equity

0.15

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-